載入...
Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T cells
Androgen deprivation is the primary therapy for recurrent prostate cancer, and agents targeting the androgen receptor (AR) pathway continue to be developed. Because androgen-deprivation therapy (ADT) has immmunostimulatory effects as well as direct antitumor effects, AR-targeted therapies have been...
Na minha lista:
| 發表在: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5873299/ https://ncbi.nlm.nih.gov/pubmed/29051161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0390 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|